Condition
Japanese Encephalitis Vaccine
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 4 (3)
Trial Status
Active Not Recruiting1
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06825312Phase 4Active Not RecruitingPrimary
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
NCT03971058Phase 4UnknownPrimary
Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.
NCT01656200Phase 4Completed
A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Showing all 3 trials